U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA ® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Phase 3 TITAN is the first registrational study to achieve statistical significance in dual primary endpoints of overall survival and radiographic progression-free survival in patients with mCSPC regardless of extent of disease
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | New Drug Applications | Pharmaceuticals | Prostate Cancer | Radiography | Statistics | Study